MX2009009996A - Composicion y metodo para tratar diabetes y trastornos metabolicos. - Google Patents

Composicion y metodo para tratar diabetes y trastornos metabolicos.

Info

Publication number
MX2009009996A
MX2009009996A MX2009009996A MX2009009996A MX2009009996A MX 2009009996 A MX2009009996 A MX 2009009996A MX 2009009996 A MX2009009996 A MX 2009009996A MX 2009009996 A MX2009009996 A MX 2009009996A MX 2009009996 A MX2009009996 A MX 2009009996A
Authority
MX
Mexico
Prior art keywords
composition
metabolic disorders
treat diabetes
diabetes
subject
Prior art date
Application number
MX2009009996A
Other languages
English (en)
Spanish (es)
Inventor
Milton Joseph Ahrens
Daryl Lee Thompson
Original Assignee
Atm Metabolics Lllp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39590291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atm Metabolics Lllp filed Critical Atm Metabolics Lllp
Publication of MX2009009996A publication Critical patent/MX2009009996A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009009996A 2007-03-19 2008-03-11 Composicion y metodo para tratar diabetes y trastornos metabolicos. MX2009009996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89548607P 2007-03-19 2007-03-19
PCT/US2008/056474 WO2008115723A1 (en) 2007-03-19 2008-03-11 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Publications (1)

Publication Number Publication Date
MX2009009996A true MX2009009996A (es) 2010-01-20

Family

ID=39590291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009996A MX2009009996A (es) 2007-03-19 2008-03-11 Composicion y metodo para tratar diabetes y trastornos metabolicos.

Country Status (8)

Country Link
US (2) US7943164B2 (enExample)
EP (1) EP2129371B1 (enExample)
JP (1) JP2010522185A (enExample)
CN (1) CN101674821B (enExample)
BR (1) BRPI0809047B8 (enExample)
CA (1) CA2685031A1 (enExample)
MX (1) MX2009009996A (enExample)
WO (1) WO2008115723A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522185A (ja) * 2007-03-19 2010-07-01 エーティーエム メタボリックス エルエルエルピー 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物
JP5524466B2 (ja) * 2008-10-31 2014-06-18 ユニテックフーズ株式会社 中性風味デザートベース
US9918489B2 (en) * 2008-12-17 2018-03-20 Mark Gorris Food-based supplement delivery system
US20100178413A1 (en) * 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
JP2011001311A (ja) * 2009-06-19 2011-01-06 Pola Chemical Industries Inc 熱産生タンパク質発現促進剤
CN102469816A (zh) * 2009-08-10 2012-05-23 斯托克里-丰康普公司 将类黄酮悬浮于饮料中的方法
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
EP2461704B1 (en) 2010-01-29 2013-10-09 Abbott Laboratories Aseptically packaged nutritional liquids comprising hmb
BR112012017690A2 (pt) 2010-01-29 2015-09-01 Abbott Lab Emulsões nutricionais compreendendo hmb de cálcio
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US8372447B2 (en) * 2010-08-03 2013-02-12 Northern Innovations And Formulations Corp. Compositions and methods for promoting weight loss and increasing energy
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
US9387219B2 (en) 2011-06-06 2016-07-12 Conopco, Inc. Edible composition
US20140127713A1 (en) 2011-06-28 2014-05-08 Femke Karina de Theije Means for the examination of body fluids
CN102772424B (zh) * 2012-06-13 2014-01-08 浙江大学 新橙皮苷在制备防治糖尿病药物中的应用
KR101396059B1 (ko) * 2012-06-25 2014-05-16 중앙대학교 산학협력단 소귀나무잎으로부터 분리된 신규 황산염 페놀성 화합물 및 이의 항산화 및 항염 용도
JP6297546B2 (ja) 2012-06-29 2018-03-20 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 結合磁性粒子及び未結合磁性粒子の処理
CN104395751B (zh) 2012-06-29 2016-10-19 皇家飞利浦有限公司 含有干扰颗粒的流体的处理
EP2875336B1 (en) 2012-07-18 2017-05-31 Koninklijke Philips N.V. Processing of a sample fluid with target components
WO2014083474A1 (en) 2012-11-30 2014-06-05 Koninklijke Philips N.V. Capture particle for selectively binding a target molecule
JP6621463B2 (ja) 2014-04-13 2019-12-18 マルマル インベストメント エスピー．ゼット オー．オー． 血糖値を低下させ、体重管理をするための健康食品組成物
US10307759B2 (en) 2014-06-25 2019-06-04 Koninklijke Philips N.V. Biosensor for the detection of target components in a sample
US20170326194A1 (en) * 2014-12-01 2017-11-16 Cape Kingdom Nutraceuticals (Pty) Ltd Therapeutic compositions
JP6594995B2 (ja) 2015-03-26 2019-10-23 コーニンクレッカ フィリップス エヌ ヴェ バイオセンサカートリッジの製造
CN105816473B (zh) * 2015-07-06 2018-04-10 武汉华纳联合药业有限公司 一种黄酮苷类组合物及其制剂和制法
JP2017105745A (ja) * 2015-12-02 2017-06-15 共栄化学工業株式会社 皮膚外用剤
US20180133243A1 (en) * 2016-11-16 2018-05-17 Holista Colltech Ltd Method and composition for crude formulations of fortified sugar for glycemic control
TWI736755B (zh) * 2017-04-03 2021-08-21 大江生醫股份有限公司 包含植物萃取物的組成物及其減少紫外線所致皮膚損傷之用途
US20220257561A1 (en) * 2019-06-07 2022-08-18 Advanced Delivery Labs Llc Compositions and methods for improving wellness
CN111387504A (zh) * 2020-04-15 2020-07-10 武汉森澜生物科技有限公司 一种含绿原酸和柚皮苷的活性提取物、提取方法及其用途
US20250213519A1 (en) * 2022-03-28 2025-07-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synergy for increasing insulin sensitivity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134233B2 (ja) 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α−グリコシル ケルセチンとその製造方法並びに用途
EP0969743B1 (en) * 1997-03-20 2004-09-15 Coventry Group, Ltd. Nutritional supplement for cardiovascular health
US7229651B2 (en) 1997-08-06 2007-06-12 Melaleuca, Inc. Dietary supplements containing natural ingredients
KR20000019716A (ko) 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
US20020068704A1 (en) 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
US20020054924A1 (en) 2000-04-13 2002-05-09 Leahy Margaret M. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US20030108627A1 (en) * 2001-09-25 2003-06-12 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
WO2004041265A1 (ja) * 2002-11-06 2004-05-21 Kao Corporation 血液流動性改善剤
US7270837B2 (en) 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2006074278A2 (en) 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
US20070092454A1 (en) 2005-10-24 2007-04-26 Colgate-Palmolive Company Oral composition containing morin
JP2010522185A (ja) 2007-03-19 2010-07-01 エーティーエム メタボリックス エルエルエルピー 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物

Also Published As

Publication number Publication date
JP2010522185A (ja) 2010-07-01
CA2685031A1 (en) 2008-09-25
BRPI0809047B1 (pt) 2020-09-01
US20080234364A1 (en) 2008-09-25
EP2129371A1 (en) 2009-12-09
CN101674821B (zh) 2013-06-26
WO2008115723A1 (en) 2008-09-25
BRPI0809047B8 (pt) 2021-05-25
BRPI0809047A2 (pt) 2014-09-02
EP2129371B1 (en) 2021-05-05
US20110118345A1 (en) 2011-05-19
US8198319B2 (en) 2012-06-12
US7943164B2 (en) 2011-05-17
CN101674821A (zh) 2010-03-17

Similar Documents

Publication Publication Date Title
MX2009009996A (es) Composicion y metodo para tratar diabetes y trastornos metabolicos.
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
ECSP10010015A (es) Inhibidores de proteasoma
UY31789A1 (es) Composiciones de insulina de super rápida actuación
MX386489B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
BR112013009142A2 (pt) "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa"
CR20120167A (es) Conjugados de niacina y ácidos grasos y sus usos
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
GB0920703D0 (en) Compositions containing satiogens and methods of use
SV2010003673A (es) Compuestos heterociclicos novedosos y usos de los mismos
BRPI0920670A8 (pt) composição nutritiva para promover o desenvolvimento e crescimento sadios
BR112012023021A2 (pt) compostos de indazol e seus usos
BR112013024025A8 (pt) Composição fluida destinada a ser aplicada na pele
UY34950A (es) Composición y método adecuado para enfermedades provocadas por fitopatógenos y método para proteger sustancias naturales de origen animal y/o vegetal
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
BRPI0924653B8 (pt) composto de ferro-oligossacarídeo, composição e uso de deste composto
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
BRPI0818007A2 (pt) composição para regular o metabolismo lipídico
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
EP2063881A4 (en) COMPOSITION AND METHOD FOR THE EFFECTIVE AND SAFE ADMINISTRATION OF HALOPYRUVATE FOR THE TREATMENT OF CANCER
BRPI0915829A2 (pt) composições que têm o objetivo de promover o desenvolvimento e crescimento de uma microflora vaginal benéfica
BRPI0905995A2 (pt) "composição conservante para ser adicionada a um produto formulado, produto a ser conservado, método de fabricação do produto e uso de uma composição"

Legal Events

Date Code Title Description
FG Grant or registration